Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD
VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX:NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based treatments, comments on the U.S. Food and Drug Administration’s (“FDA”) decision to not approve Lykos Therapeutics’ new drug application for MDMA (midomafetamine capsules) used in combination with psychological intervention for individuals with post-traumatic stress disorder (“PTSD”). According to a news release issued by Lykos Therapeutics, the FDA has requested that an additional Phase 3 study be conducted to study the safety and efficacy of MDMA further.
Related news for (NUMIF)
- Numinus Wellness Inc. Announces CFO Transition
- Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
- Numinus Wellness Announces Corporate Update
- Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
- Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care